Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL study of osimertinib in elderly EGFR T790M-positive NSCLC after prior EGFR-TKI
jRCTs071180002Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180002.